Clinical Trial Detail

NCT ID NCT02228382
Title Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Pfizer
Indications

chronic myeloid leukemia

Therapies

Bosutinib

Age Groups: adult senior

Additional content available in CKB BOOST